Table 4.
Baseline data on the patients, continuous variables
| |
Double dose of statin |
Statin + ezetimibe |
p value | ||
|---|---|---|---|---|---|
| mean ± sd | n | mean ± sd | n | ||
| age |
62.6 ± 9.5 |
56 |
61.7 ± 11.1 |
53 |
0.4949 |
| TC |
218.2 ± 27.2 |
56 |
212.5 ± 30.1 |
53 |
0.3567 |
| TG |
161.9 ± 88.3 |
56 |
146.7 ± 95.2 |
53 |
0.1803 |
| HDL-C |
54.7 ± 9.6 |
56 |
56.7 ± 15.2 |
53 |
0.9734 |
| LDL-C |
135.2 ± 22.6 |
56 |
130.6 ± 19.2 |
53 |
0.5463 |
| non HDL-C |
163.6 ± 25.7 |
56 |
155.9 ± 26.9 |
52 |
0.1133 |
| RLP-C |
6.3 ± 3.9 |
56 |
6.1 ± 4.8 |
52 |
0.4756 |
| apo A1 |
146.6 ± 16.6 |
44 |
144.2 ± 19.2 |
40 |
0.3288 |
| apo B |
111.4 ± 18.2 |
44 |
101.8 ± 16.5 |
40 |
0.0152 |
| apo E |
4.1 ± 0.9 |
44 |
3.8 ± 1.0 |
40 |
0.1604 |
| MDA-LDL |
157.0 ± 62.0 |
12 |
112.6 ± 27.7 |
9 |
0.0549 |
| sd-LDL |
52.2 ± 17.9 |
56 |
46.2 ± 16.0 |
52 |
0.0484 |
| Fasting glucose |
132.7 ± 32.5 |
56 |
141.5 ± 33.1 |
53 |
0.1108 |
| Fasting insulin |
10.9 ± 7.0 |
35 |
13.8 ± 12.5 |
28 |
0.5381 |
| ALT |
23.6 ± 10.9 |
56 |
24.7 ± 12.5 |
53 |
0.8318 |
| AST |
23.1 ± 12.1 |
52 |
23.7 ± 12.2 |
49 |
0.8541 |
| γ-GTP |
30.2 ± 21.7 |
53 |
28.6 ± 26.6 |
47 |
0.3248 |
| CK |
116.7 ± 58.2 |
54 |
122.5 ± 88.3 |
51 |
0.9642 |
| Creatinine |
0.81 ± 0.28 |
56 |
0.79 ± 0.24 |
51 |
0.9627 |
| HbA1C |
7.15 ± 1.32 |
56 |
7.25 ± 0.64 |
53 |
0.6294 |
| hs-CRP | 1114 ± 1493 | 56 | 922 ± 1119 | 51 | 0.6025 |
The data were evaluated using the Wilcoxon test.